Nicholas C. Turner
YOU?
Author Swipe
View article: The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial Open
Purpose: ctDNA dynamic levels may identify patients who will respond to therapy. We assessed ctDNA baseline levels and on-treatment dynamics in patients with advanced breast cancer on the plasmaMATCH trial with mutation-targeted therapies …
View article: PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i> -Mutated Solid Tumors and in Preclinical Models
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i> -Mutated Solid Tumors and in Preclinical Models Open
Purpose: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor–positive breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degradation of mutated p110α. PI3K inhibitors have generally s…
View article: Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
AE profile for camizestrant in combination with abemaciclib, palbociclib, or ribociclib (irrespective of causality); AEs reported in ≥20% of patients.a
View article: Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
ORR, CBR24, and median PFS for (A) camizestrant in combination with abemaciclib, palbociclib, or ribociclib; (B) subgroup analysis pooled across all camizestrant + CDK4/6i combinations. NC is represented by an arrowed line in the plots and…
View article: Supplementary Figure S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Abemaciclib, palbociclib, and ribociclib concentrations at steady state
View article: Supplementary Figure S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
CONSORT diagrams
View article: Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
ESR1m ctDNA dynamics for each CDK4/6i + camizestrant combination. (Top) waterfall plot showing percentage change in ESR1m summed VAF at C2D1 compared with C1D1 in each evaluable patient. (Middle) vector plot showing absolute ESR1m ctDNA ch…
View article: Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
ORR, CBR24, and median PFS for subgroup analysis across pooled camizestrant 75 mg combination arms
View article: Supplementary Table S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Study representativeness
View article: Data from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Data from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Purpose:This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor–positive, HER2− advanced breast cancer.Patients and Methods:SERENA-1 (NCT0361…
View article: Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Time course of heart rate reductions and QTcF
View article: Supplementary Table S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Camizestrant PK parameters
View article: Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.
View article: Supplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Percentage change in ESR1m variants
View article: Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
AEs leading to dose reduction or discontinuation in patients treated with camizestrant 75, 150, or 300 mg combined with either abemaciclib, palbociclib, or ribociclib. Description data are presented as number and % of patients. N, number; …
View article: Supplementary Table S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Adverse event profile for camizestrant
View article: Supplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Safety summary of camizestrant
View article: Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis Open
National Institute of Health Research, Breast Cancer Research Foundation, Dr Josef Steiner Cancer Research Award 2019, Basser Gray Prime Award 2020, Cancer Research UK, Sir Jeffrey Cheah Early Career Fellowship, the Mats Paulsson Foundatio…
View article: Monitoring for pneumonitis in breast cancer patients treated with trastuzumab deruxtecan: a single-centre experience
Monitoring for pneumonitis in breast cancer patients treated with trastuzumab deruxtecan: a single-centre experience Open
Background: Trastuzumab deruxtecan (T-DXd) is a highly effective treatment for human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer. Following two fatal pneumonitis cases within 6 months of introduci…
View article: LOX inhibition disrupts a collagen-integrin–MYC axis as a translatable targeting strategy in invasive lobular carcinoma
LOX inhibition disrupts a collagen-integrin–MYC axis as a translatable targeting strategy in invasive lobular carcinoma Open
Invasive lobular carcinoma (ILC) accounts for 15% of breast cancers yet lacks specific therapy because ILCs are underrepresented in clinical trials and preclinical models are lacking. We established intraductal xenograft models to test whe…
View article: Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Purpose: This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor–positive, HER2− advanced breast cancer. Patients and Methods: SERENA-1 (NCT0…
View article: 681. ENDOCANNABINOIDS AND INTRUSIVE MEMORIES: EVIDENCE FOR A ROLE OF ANANDAMIDE FROM TWO EXPERIMENTAL HUMAN STUDIES
681. ENDOCANNABINOIDS AND INTRUSIVE MEMORIES: EVIDENCE FOR A ROLE OF ANANDAMIDE FROM TWO EXPERIMENTAL HUMAN STUDIES Open
Background Preclinical evidence strongly suggests that the endocannabinoid system (particularly the ligands anandamide and 2-AG) is involved in trauma responses and negative emotional memories, which are relevant to posttraumatic stress di…
View article: Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
MANIFEST Consortium List of Authors
View article: Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Summary:Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-chan…
View article: Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Notable large-scale immuno-oncology consortia formed in the recent era.
View article: <i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis Open
PURPOSE The PENELOPE-B trial (ClinicalTrials.gov identifier: NCT01864746 ) recruited patients with hormone receptor+/human epidermal growth factor receptor 2– early breast cancer without a pathological complete response after taxane-contai…